Regencell Bioscience Holdings (RGC) is back in focus after disclosing cooperation with a U.S. Department of Justice investigation into trading in its shares, alongside mounting legal costs and going concern warnings.

At a share price of $6.37, Regencell Bioscience Holdings has seen sharp selling pressure recently, with the 30 day share price return down 68.13% and the year to date share price return down 68.99%. The three year total shareholder return remains very large, hinting at how sentiment has swung as the Department of Justice investigation, going concern warnings, and lack of revenue have refocused attention on risk rather than past gains.

If you want to see what else is moving as investors reassess higher risk stories, it could be worth scanning for 20 top founder-led companies

With Regencell Bioscience Holdings now trading well below its recent offering price, yet still showing a very large three year total shareholder return, the key question is whether current risks are overdiscounted or if the market is already assuming future success.

Preferred Price-to-Book Multiple of 2,588x: Is It Justified?

Regencell Bioscience Holdings currently looks expensive on a simple yardstick, with its price implying a very high valuation compared to the book value of its equity.

The price to book ratio compares the market value of the company to the accounting value of its net assets, so it is often used where earnings are not yet positive. For RGC, this multiple is 2,588.3x, while the company reports no revenue and a net loss of $7.05m. This means investors are effectively paying a very large premium over the balance sheet value for a business still in the development stage.

Against peers, that premium stands out sharply. The US pharmaceuticals industry averages a P/B of 2.4x, and RGC also screens as expensive relative to its direct peer group average of 6.4x. Both comparisons underline how far current pricing sits above sector norms, even before considering that RGC remains unprofitable and has a negative return on equity.

Result: Price-to-book of 2,588.3x (OVERVALUED)

However, the Department of Justice investigation and the company’s ongoing losses with no revenue mean that Regencell Bioscience Holdings could still face sharp swings in sentiment.

Next Steps

Given how cautious this Regencell Bioscience Holdings story sounds, it makes sense to check the underlying data yourself and decide quickly where you stand. Start by weighing the 3 important warning signs.

Looking for more investment ideas beyond Regencell Bioscience Holdings?

If Regencell Bioscience Holdings has highlighted how concentrated single stock risk can feel, you can use that insight to broaden your opportunity set with a few focused stock lists.

• Spot potential turnaround stories by checking out 20 elite penny stocks with strong financials that combine smaller market sizes with stronger balance sheets and business fundamentals than many expect.
• Target quality at a more grounded price by reviewing the 44 high quality undervalued stocks that pair solid cash flows with healthier financial positions.
• Reduce portfolio stress by focusing on 74 resilient stocks with low risk scores that score better on balance sheet strength, earnings consistency, and overall risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.